Can we predict which patients are likely to develop severe complications following reconstruction for osteoradionecrosis?

Br J Oral Maxillofac Surg. 2013 Dec;51(8):707-13. doi: 10.1016/j.bjoms.2013.08.017. Epub 2013 Oct 28.

Abstract

High morbidity has been reported for free vascularised reconstruction for osteoradionecrosis (ORN) and there are no apparent risk factors. A single nucleotide polymorphism in the transforming growth factor beta 1 gene (TGF-β1) has been implicated in the cause of ORN and may also predict these complications. We studied a series of 30 consecutive patients who had had reconstruction for severe ORN with free tissue transfer in relation to their outcomes and complications for a number of risk factors including TFG-β1 genotype, age, sex, comorbidities, site and stage of tumour, type of initial operation, and dose of radiotherapy or chemoradiotherapy. Two patients died and 2 flaps failed. Using the Clavien-Dindo classification, 16 patients developed grade III complications and 6 grade II. Median (IQR) duration of inpatient stay was 19.5 (12-25) days and the median (IQR) duration of outpatient treatment was 6 (4-11) weeks. No specific risk factors for postoperative complications were identified. In view of the severity and unpredictability of the complications, careful preoperative counselling of patients is essential.

Keywords: Complications; Osteoradionecrosis; Reconstruction.

Publication types

  • Comparative Study

MeSH terms

  • Age Factors
  • Aged
  • Ambulatory Care
  • Chemoradiotherapy
  • Female
  • Forecasting
  • Free Tissue Flaps / blood supply
  • Free Tissue Flaps / transplantation
  • Genotype
  • Hospitalization
  • Humans
  • Jaw Diseases / surgery*
  • Length of Stay
  • Male
  • Middle Aged
  • Mouth Neoplasms / radiotherapy
  • Mouth Neoplasms / surgery
  • Neoplasm Staging
  • Osteoradionecrosis / surgery*
  • Plastic Surgery Procedures / methods*
  • Polymorphism, Single Nucleotide / genetics
  • Postoperative Complications*
  • Radiotherapy Dosage
  • Reoperation
  • Risk Factors
  • Sex Factors
  • Thymine
  • Transforming Growth Factor beta1 / genetics
  • Treatment Outcome

Substances

  • Transforming Growth Factor beta1
  • Thymine